Mylan Pharmaceuticals Inc 2022-01-26 Health critical FDA
Health · FDA · Recall #FDA-D-0462-2022
Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC… Recall
Issued January 26, 2022 · Mylan Pharmaceuticals Inc
In January 2022, Mylan Pharmaceuticals Inc recalled the Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC…, a critical health recall reported by the FDA. Affected owners are eligible for a voluntary. Here is what the hazard is and exactly what to do about it.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Labeling: Missing Label: label missing from some Semglee prefilled pens.
What you should do
- 1 Stop using Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Mylan Pharmaceuticals Inc to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Mylan Pharmaceuticals Inc
- Category
- Health
- Recall date
- January 26, 2022
- Units affected
- Not reported
- Sold at
- Nationwide in the USA and Thailand.
- Recall number
- FDA-D-0462-2022
- Made in
- United States
- Issuing agency
- FDA
In context
- Mylan Pharmaceuticals Inc has 4 recalls in our database, including 3 rated Critical.
- We're tracking 3,576 Health recalls in our database.
- This is the 870th Health recall we've logged in 2022.